Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05328050
Recruiting Observational

Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)

NCT05328050 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Phase
Observational
Started
2021-09-01
Last updated
2022-04-28

Condition(s) studied

AchondroplasiaHypochondroplasia

Investigational drug(s) / intervention(s)

Registry

Registry: observational, data collection

Study summary

This registry is a observational, single-center study designed to collect clinical data on patients with achondroplasia and hypochondroplasia.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Confirmed diagnosis of achondroplasia/hypochondroplasia * Patients (and/or Parents legal guardian when required) able to provide informed consent Exclusion Criteria: * Absence of diagnosis of achondroplasia/hypochondroplasia * Patients (and/or Parents legal guardian when required) not able to provide informed consent

Primary outcome measure(s)

  • Registry of Achondroplasia and Hypochondroplasia Patients — 10 years
    Collection of medical information of achondroplasia and hypochndroplasia patients intended for use in future research studies.

Trial sites (1)

FacilityCityRegionStatus
Medical Genetics Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Milan Italy Recruiting

More Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico trials in Italy

Risk Factors, Incidence, and Clinical Impact of Intraluminal Thrombosis Following FET and TEVAR Starting soon
Platelet-Rich Plasma Injections From Cord Blood + Penile Traction vs. Penile Traction Alone in Patients With Peyronie's Disease. Open-label, Single-center Randomized Study Recruiting
Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis Recruiting
DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD Recruiting
Genetic Diagnosis and Personalized Medicine for Patients With Epilepsy Recruiting

Other trials for the same condition

A Multicenter Multinational Observational Study of Children With Hypochondroplasia Recruiting
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia Enrolling by invitation
Extension Study of Infigratinib in Children With Achondroplasia (ACH) Enrolling by invitation
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia Recruiting
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05328050 on ClinicalTrials.gov ↗ ← All trials in Italy